Elevated Pretreatment Fibrinogen-to-Lymphocyte Percentage Ratio Predict Tumor Staging and Poor Survival in Non-Small Cell Lung Cancer Patients with Chemotherapy or Surgery Combined with Chemotherapy

References

• Bray F , Ferlay J , Soerjomataram I , Siegel RL , Torre LA , Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin . 2018;68(6):394–424. doi:10.3322/caac.21492 30207593
   PubMed Web of Science ®Google Scholar
• Xie Y , Zhang Y , Du L , et al. Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer. Mol Oncol . 2018;12(5):648–658. doi:10.1002/1878-0261.12188 29504701
   PubMed Web of Science ®Google Scholar
• Herbst RS , Morgensztern D , Boshoff C . The biology and management of non-small cell lung cancer. Nature . 2018;553(7689):446–454. doi:10.1038/nature25183 29364287
   PubMed Web of Science ®Google Scholar
• Siegel R , Miller K , Jemal A . Cancer statistics, 2020. CA Cancer J Clin . 2020;70(1):7–30. doi:10.3322/caac.21590 31912902
   PubMed Web of Science ®Google Scholar
• Jett J , Schild S , Kesler K , Kalemkerian G . Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest . 2013;143(5):e400S–e419S. doi:10.1378/chest.12-2363 23649448
   PubMed Web of Science ®Google Scholar
• Hattori A , Takamochi K , Oh S , Suzuki K . New revisions and current issues in the eighth edition of the TNM classification for non-small cell lung cancer. Jpn J Clin Oncol . 2019;49(1):3–11. doi:10.1093/jjco/hyy142 30277521
   PubMed Web of Science ®Google Scholar
• Wang W , Bian C , Xia D , et al. Combining carcinoembryonic antigen and platelet to lymphocyte ratio to predict brain metastasis of resected lung adenocarcinoma patients. Biomed Res Int . 2017;2017:8076384.28642881
   PubMed Web of Science ®Google Scholar
• Syrigos K , Grapsa D , Sangare R , et al. Prospective assessment of clinical risk factors and biomarkers of hypercoagulability for the identification of patients with lung adenocarcinoma at risk for cancer-associated thrombosis: the observational ROADMAP-CAT study. oncologist . 2018;23(11):1372–1381. doi:10.1634/theoncologist.2017-0530 30104289
   PubMed Web of Science ®Google Scholar
• Crusz SM , Balkwill FR . Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol . 2015;12(10):584–596. doi:10.1038/nrclinonc.2015.105 26122183
   PubMed Web of Science ®Google Scholar
• Fang L , Xu Q , Qian J , Zhou JY . Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer. Onco Targets Ther . 2021;14:53–65. doi:10.2147/OTT.S281251 33442266
   PubMed Web of Science ®Google Scholar
• Ikwegbue PC , Masamba P , Mbatha LS , Oyinloye BE , Kappo AP . Interplay between heat shock proteins, inflammation and cancer: a potential cancer therapeutic target. Am J Cancer Res . 2019;9(2):242–249.30906626
   PubMed Web of Science ®Google Scholar
• Michels N , van Aart C , Morisse J , Mullee A , Huybrechts I . Chronic inflammation towards cancer incidence: a systematic review and meta-analysis of epidemiological studies. Crit Rev Oncol Hematol . 2021;157:103177. doi:10.1016/j.critrevonc.2020.103177 33264718
   PubMed Web of Science ®Google Scholar
• Takahashi Y , Kawamura M , Hato T , Harada M , Matsutani N , Horio H . Neutrophil-lymphocyte ratio as a prognostic marker for lung adenocarcinoma after complete resection. World J Surg . 2016;40(2):365–372. doi:10.1007/s00268-015-3275-2 26493696
   PubMed Web of Science ®Google Scholar
• Winther-Larsen A , Aggerholm-Pedersen N , Sandfeld-Paulsen B . Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis. Syst Rev . 2021;10(1):40. doi:10.1186/s13643-021-01585-w 33509254
   PubMed Web of Science ®Google Scholar
• Gu X , Sun S , Gao XS , et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3430 patients. Sci Rep . 2016;6(1):23893. doi:10.1038/srep23893 27025911
   PubMed Web of Science ®Google Scholar
• Yang HB , Xing M , Ma LN , Feng LX , Yu Z . Prognostic significance of neutrophil-lymphocyteratio/platelet-lymphocyteratioin lung cancers: a meta-analysis. Oncotarget . 2016;7(47):76769–76778. doi:10.18632/oncotarget.12526 27732958
   PubMed Web of Science ®Google Scholar
• Hou C , Jiang F , Ma H , et al. Prognostic role of preoperative platelet, fibrinogen, and D-dimer levels in patients with non-small cell lung cancer: a multicenter prospective study. Thorac Cancer . 2019;10(2):304–311. doi:10.1111/1759-7714.12956 30609303
   PubMed Web of Science ®Google Scholar
• Abdol Razak NB , Jones G , Bhandari M , Berndt MC , Metharom P . Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers . 2018;10(10):10. doi:10.3390/cancers10100380
   PubMed Web of Science ®Google Scholar
• Lebrett MB , Crosbie EJ , Smith MJ , Woodward ER , Evans DG , Crosbie PAJ . Targeting lung cancer screening to individuals at greatest risk: the role of genetic factors. J Med Genet . 2021;58(4):217–226. doi:10.1136/jmedgenet-2020-107399 33514608
   PubMed Web of Science ®Google Scholar
• Chevallier M , Borgeaud M , Addeo A , Friedlaender A . Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol . 2021;12(4):217–237. doi:10.5306/wjco.v12.i4.217 33959476
   PubMed Web of Science ®Google Scholar
• Lindeman N , Cagle P , Beasley M , et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the college of American pathologists, international association for the study of lung cancer, and association for molecular pathology. J Thorac Oncol . 2013;8(7):823–859. doi:10.1097/JTO.0b013e318290868f 23552377
   PubMed Web of Science ®Google Scholar
• Veatch J , Jesernig B , Kargl J , et al. KRASEndogenous CD4 T cells recognize neoantigens in lung cancer patients, including recurrent oncogenic and () driver mutations. Cancer Immunol Res . 2019;7(6):910–922. doi:10.1158/2326-6066.CIR-18-0402 31043415
   PubMed Web of Science ®Google Scholar
• Liu S , Dong Z , Wu S , et al. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. Lung Cancer . 2018;125:86–92. doi:10.1016/j.lungcan.2018.09.010 30429043
   PubMed Web of Science ®Google Scholar
• Schalper K , Brown J , Carvajal-Hausdorf D , et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst . 2015;107(3):3. doi:10.1093/jnci/dju435
   Google Scholar
• Matiello J , Dal Pra A , Zardo L , Silva R , Berton DC . Impacts of post-radiotherapy lymphocyte count on progression-free and overall survival in patients with stage III lung cancer. Thorac Cancer . 2020;11(11):3139–3144. doi:10.1111/1759-7714.13621 32956564
   PubMed Web of Science ®Google Scholar
• Bestari MB , Agustanti N . Obstructive jaundice due to pancreatic metastasis from non-small cell lung cancer. Acta Med Indones . 2013;45(3):216–219.24045392
   PubMedGoogle Scholar
• Page MJ , Thomson GJA , Nunes JM , et al. Serum amyloid A binds to fibrin(ogen), promoting fibrin amyloid formation. Sci Rep . 2019;9(1):3102. doi:10.1038/s41598-019-39056-x 30816210
   PubMed Web of Science ®Google Scholar
• Guan J , Xiao N , Qiu C , et al. Fibrinogen is associated with EGFR mutation status and lymphatic metastasis in non-small cell lung cancer. Oncol Lett . 2019;17(1):739–746. doi:10.3892/ol.2018.9652 30655825
   PubMed Web of Science ®Google Scholar
• Qi Y , Fu J . Research on the coagulation function changes in non small cell lung cancer patients and analysis of their correlation with metastasis and survival. J BUON . 2017;22(2):462–467.28534370
   PubMed Web of Science ®Google Scholar
• Zheng S , Shen J , Jiao Y , et al. Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity. Cancer Sci . 2009;100(5):859–865. doi:10.1111/j.1349-7006.2009.01115.x 19302289
   PubMed Web of Science ®Google Scholar
• Atagi S , Sone S , Fukuta K , Ogura T . Inhibition by fibrin coagulation of lung cancer cell destruction by human interleukin-2-activated killer cells. Jpn J Canc Res . 1992;83(10):1088–1094. doi:10.1111/j.1349-7006.1992.tb02726.x
   PubMedGoogle Scholar
• Palumbo JS , Potter JM , Kaplan LS , Talmage K , Jackson DG , Degen JL . Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res . 2002;62(23):6966–6972.12460914
   PubMed Web of Science ®Google Scholar
• Iseki Y , Shibutani M , Maeda K , et al. The impact of the preoperative peripheral lymphocyte count and lymphocyte percentage in patients with colorectal cancer. Surg Today . 2017;47(6):743–754. doi:10.1007/s00595-016-1433-2 27783149
   PubMed Web of Science ®Google Scholar
• Zhang Y , Cao J , Deng Y , et al. Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer. Clinics . 2020;75:e993. doi:10.6061/clinics/2020/e993 32130355
   PubMed Web of Science ®Google Scholar
• Lim JU , Yeo CD , Kang HS , et al. Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion. Sci Rep . 2019;9(1):4721. doi:10.1038/s41598-019-41289-9 30886226
   PubMed Web of Science ®Google Scholar
• Li SQ, Jiang YH, Lin J, et al. Albumin-to-firinogen ratio as a promising biomarker to predict clinical outcome of non-small cell lung cancer individuals. Cancer Med. 2018;7(4):1221-1231. doi:10.1002/cam4.1428
   Google Scholar
• Davalos D , Akassoglou K . Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol . 2012;34(1):43–62. doi:10.1007/s00281-011-0290-8 22037947
   PubMed Web of Science ®Google Scholar
• Perisanidis C , Psyrri A , Cohen EE , et al. Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev . 2015;41(10):960–970. doi:10.1016/j.ctrv.2015.10.002 26604093
   PubMed Web of Science ®Google Scholar
• Mantovani A , Allavena P , Sica A , Balkwill F . Cancer-related inflammation. Nature . 2008;454(7203):436–444. doi:10.1038/nature07205 18650914
   PubMed Web of Science ®Google Scholar
• Balkwill F , Mantovani A . Inflammation and cancer: back to Virchow? Lancet . 2001;357(9255):539–545. doi:10.1016/S0140-6736(00)04046-0 11229684
   PubMed Web of Science ®Google Scholar
• Kolodziejczyk J , Ponczek MB . The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression. Contemp Oncol . 2013;17(2):113–119. doi:10.5114/wo.2013.34611
   Google Scholar
• Palumbo JS , Kombrinck KW , Drew AF , et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood . 2000;96(10):3302–3309. doi:10.1182/blood.V96.10.3302 11071621
   PubMed Web of Science ®Google Scholar